Is Satellos Bioscience Inc. (MSLE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 19.4% / 30% | 0.2% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 19.4% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 95.7% / 33% | 0.9% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 19.4% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 95.7% / 33% | 0.9% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -87.6% | |
| Return on Assets (ROA) | -54.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$17M |
| Free Cash Flow | -$17M |
| Current Ratio | 10.7 |
| Total Assets | $51M |
Price & Trading
| Last Close | $6.93 |
| 50-Day MA | $10.14 |
| 200-Day MA | $6.88 |
| Avg Volume | 62K |
| Beta | 0.7 |
|
52-Week Range
$4.52
| |
About Satellos Bioscience Inc. (MSLE)
Satellos Bioscience Inc., a biotechnology company, develops medicines to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247 an oral, small-molecule drug candidate for the treatment of Duchenne muscular dystrophy disease. The company has a license agreement the with Ottawa Hospital Research Institute (OHRI); and an option agreement with the University of British Columbia. Satellos Bioscience Inc. was founded in 2018 and is headquartered in Toronto, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Satellos Bioscience Inc. (MSLE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Satellos Bioscience Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Satellos Bioscience Inc.'s debt ratio?
Satellos Bioscience Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are Satellos Bioscience Inc.'s key financial metrics?
Satellos Bioscience Inc. has a market capitalization of $129M, trailing P/E ratio of 2.4. Return on equity stands at -87.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.